Objectives: To compare the long-term functional and oncological results between laparoscopic radiofrequency ablation (LRFA) and laparoscopic partial nephrectomy (LPN) in selected clinical T1a (cT1a) renal tumor patients. Methods: We retrospectively analyzed the medical records of patients with cT1a renal tumors who had LRFA or LPN at our institution between February 2006 and February 2015. Student's t test was used to compare the perioperative data between the two groups. Survival analyses were calculated using the Kaplan-Meier method. Results: A total of 179 patients were included in the study. Patients in the LRFA cohort were significantly older and had higher American Society of Anesthesiologists sore than in the LPN cohort. The LRFA group had a significantly lower mean blood loss than the LPN group (p = 0.03). The percent decrease of GFR in the LRFA group was significantly lower than in the LPN group (p = 0.021). The 5-year overall, cancer-specific and disease-free survival were 93.3 vs. 94.6%, 98.0 vs. 98.5% and 97.1 vs. 97.3%, for LRFA and LPN, respectively (all p value >0.05). Conclusions: The excellent perioperative results, long-term functional and oncological outcomes of LRFA confirm that this technique is safe, nephron sparing and oncologically effective for the treatment of cT1a renal tumors.

Keywords:
Partial nephrectomy, Radiofrequency ablation, Kidney tumor, Laparoscopic
1.
Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, et al: Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013;105:175-201.
2.
Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, et al: EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015;67:913-924.
3.
Antonelli A, Ficarra V, Bertini R, Carini M, Carmignani G, Corti S, Longo N, Martorana G, Minervini A, Mirone V, et al: Elective partial nephrectomy is equivalent to radical nephrectomy in patients with clinical T1 renal cell carcinoma: results of a retrospective, comparative, multi-institutional study. BJU Int 2012;109:1013-1018.
4.
Gill IS, Kavoussi LR, Lane BR, Blute ML, Babineau D, Colombo JR Jr, Frank I, Permpongkosol S, Weight CJ, Kaouk JH, et al: Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol 2007;178:41-46.
5.
Park H, Byun SS, Kim HH, Lee SB, Kwon TG, Jeon SH, Kang SH, Seo SI, Oh TH, Jeon YS, et al: Comparison of laparoscopic and open partial nephrectomies in T1a renal cell carcinoma: a Korean multicenter experience. Korean J Urol 2010;51:467-471.
6.
Van Poppel H, Becker F, Cadeddu JA, Gill IS, Janetschek G, Jewett MA, Laguna MP, Marberger M, Montorsi F, Polascik TJ, et al: Treatment of localised renal cell carcinoma. Eur Urol 2011;60:662-672.
7.
Thompson RH: Radical nephrectomy: too radical for small renal masses? Lancet 2006;368:823-824.
8.
Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, Marechal JM, Klotz L, Skinner E, Keane T, et al: A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2007;51:1606-1615.
9.
Bandi G, Hedican SP, Nakada SY: Current practice patterns in the use of ablation technology for the management of small renal masses at academic centers in the United States. Urology 2008;71:113-117.
10.
Ji C, Li X, Zhang S, Gan W, Zhang G, Zeng L, Yan X, Liu T, Lian H, Guo H: Laparoscopic radiofrequency ablation of renal tumors: 32-month mean follow-up results of 106 patients. Urology 2011;77:798-802.
11.
Kim SD, Yoon SG, Sung GT: Radiofrequency ablation of renal tumors: four-year follow-up results in 47 patients. Korean J Radiol 2012;13:625.
12.
Park S, Anderson JK, Matsumoto ED, Lotan Y, Josephs S, Cadeddu JA: Radiofrequency ablation of renal tumors: intermediate-term results. J Endourol 2006;20:569-573.
13.
Lian H, Guo H, Zhang G, Yang R, Gan W, Li X, Ji C, Liu J: Single-center comparison of complications in laparoscopic and percutaneous radiofrequency ablation with ultrasound guidance for renal tumors. Urology 2012;80:119-124.
14.
Ramirez D, Ma YB, Bedir S, Antonelli JA, Cadeddu JA, Gahan JC: Laparoscopic radiofrequency ablation of small renal tumors: long-term oncologic outcomes. J Endourol 2014;28:330-334.
15.
Wah TM, Irving HC, Gregory W, Cartledge J, Joyce AD, Selby PJ: Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int 2014;113:416-428.
16.
Psutka SP, Feldman AS, McDougal WS, McGovern FJ, Mueller P, Gervais DA: Long-term oncologic outcomes after radiofrequency ablation for T1 renal cell carcinoma. Eur Urol 2013;63:486-492.
17.
Ma Y, Bedir S, Cadeddu JA, Gahan JC: Long-term outcomes in healthy adults after radiofrequency ablation of T1a renal tumours. BJU Int 2014;113:51-55.
18.
Yang R, Lian H, Zhang G, Wang W, Gan W, Li X, Yan X, Zhang S, Zhao X, Guo H: Laparoscopic radiofrequency ablation with intraoperative contrast-enhanced ultrasonography for T1bN0M0 renal tumors: initial functional and oncologic outcomes. J Endourol 2014;28:4-9.
19.
Farrell MA, Charboneau WJ, DiMarco DS, Chow GK, Zincke H, Callstrom MR, Lewis BD, Lee RA, Reading CC: Imaging-guided radiofrequency ablation of solid renal tumors. AJR Am J Roentgenol 2003;180:1509-1513.
20.
Lucas SM, Stern JM, Adibi M, Zeltser IS, Cadeddu JA, Raj GV: Renal function outcomes in patients treated for renal masses smaller than 4 cm by ablative and extirpative techniques. J Urol 2008;179:75-79; discussion 79-80.
21.
Wingo MS, Leveillee RJ: Central and deep renal tumors can be effectively ablated: radiofrequency ablation outcomes with fiberoptic peripheral temperature monitoring. J Endourol 2008;22:1261-1267.
22.
Dindo D, Demartines N, Clavien PA: Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-213.
23.
Campbell SC, Novick AC, Belldegrun A, Blute ML, Chow GK, Derweesh IH, Faraday MM, Kaouk JH, Leveillee RJ, Matin SF, et al: Guideline for management of the clinical T1 renal mass. J Urol 2009;182:1271-1279.
24.
Sommer CM, Lemm G, Hohenstein E, Stampfl U, Bellemann N, Teber D, Rassweiler J, Kauczor HU, Radeleff BA, Pereira PL: Bipolar versus multipolar radiofrequency (RF) ablation for the treatment of renal cell carcinoma: differences in technical and clinical parameters. Int J Hyperthermia 2013;29:21-29.
25.
Sommer CM, Lemm G, Hohenstein E, Bellemann N, Stampfl U, Goezen AS, Rassweiler J, Kauczor HU, Radeleff BA, Pereira PL: CT-guided bipolar and multipolar radiofrequency ablation (RF ablation) of renal cell carcinoma: specific technical aspects and clinical results. Cardiovasc Intervent Radiol 2013;36:731-737.
26.
Salagierski M, Salagierski M: Haemostatic radiofrequency ablation assisted partial nephrectomy: is radiofrequency energy a viable solution? Urol Int 2008;81:77-81.
27.
Salagierski M, Salagierski M, Salagierska-Barwinska A, Sosnowski M: Probability of ten-year survival in metastatic renal cell carcinoma. Urol Int 2008;80:335-337.
28.
Vricella GJ, Ponsky LE, Cadeddu JA: Ablative technologies for urologic cancers. Urol Clin North Am 2009;36:163-178, viii.
29.
Jacomides L, Ogan K, Watumull L, Cadeddu JA: Laparoscopic application of radio frequency energy enables in situ renal tumor ablation and partial nephrectomy. J Urol 2003;169:49-53; discussion 53.
30.
Margulis V, Matsumoto ED, Lindberg G, Tunc L, Taylor G, Sagalowsky AI, Cadeddu JA: Acute histologic effects of temperature-based radiofrequency ablation on renal tumor pathologic interpretation. Urology 2004;64:660-663.
31.
Karam JA, Ahrar K, Vikram R, Romero CA, Jonasch E, Tannir NM, Rao P, Wood CG, Matin SF: Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int 2013;111:997-1005.
32.
Weight CJ, Kaouk JH, Hegarty NJ, Remer EM, O'Malley CM, Lane BR, Gill IS, Novick AC: Correlation of radiographic imaging and histopathology following cryoablation and radio frequency ablation for renal tumors. J Urol 2008;179:1277-1281; discussion 1281-1283.
33.
Raman JD, Stern JM, Zeltser I, Kabbani W, Cadeddu JA: Absence of viable renal carcinoma in biopsies performed more than 1 year following radio frequency ablation confirms reliability of axial imaging. J Urol 2008;179:2142-2145.
34.
Xu B, Zhang Q, Jin J: Retroperitoneal laparoscopic partial nephrectomy for moderately complex renal hilar tumors. Urol Int 2014;92:400-406.
35.
Thompson RH, Atwell T, Schmit G, Lohse CM, Kurup AN, Weisbrod A, Psutka SP, Stewart SB, Callstrom MR, Cheville JC, et al: Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol 2015;67:252-259.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.